Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454026 | 1.00 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3MMP1MMP2 | |
| SCHEMBL455165 | 1.00 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3MMP1MMP2 | |
| SCHEMBL7427732 | 0.80 | FDPS (0.32) | DPP7FDPS | |
| SCHEMBL678404 | 0.77 | SLC6A2 (0.30) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7111674 | 0.76 | FDPS (0.32) | DPP7FDPS | |
| SCHEMBL6039579 | 0.76 | FDPS (0.37) | DPP7FDPS | |
| SCHEMBL678969 | 0.74 | SLC6A3 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19407706 | 0.74 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3MMP1MMP2 | |
| SCHEMBL18828088 | 0.74 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3MMP1MMP2 | |
| SCHEMBL8904036 | 0.74 | HRH3 (0.40) | SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313891-A1 | NEURONAL NICOTINIC AGONISTS AND METHODS OF USE | ABBVIE INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2099795-B1 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBVIE BAHAMAS LTD (BS) | 2015-08-19 | — | — | EP | disclosed |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES | 2015-06-11 | — | — | US | disclosed |
| US-8987453-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2231672-B1 | BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8853241-B2 | Biaryl substituted azabicyclic alkane derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8802693-B1 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130317056-A1 | NEURONAL NICOTINIC AGONISTS AND METHODS OF CORRELATING COMT SNPS | ABBVIE INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130317054-A1 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE | ABBVIE INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130317055-A1 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE | ABBVIE INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2009067579-A1 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY MODULATORS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067578-A2 | NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067586-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008058096-A9 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LAB (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008058096-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| WO-2005121090-A1 | SUBSTITUTED PIPERIDINES THAT HAVE ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | SLC6A2 107/4885SLC6A4 290/4885SLC6A3 128/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | SLC6A2 1291/4885SLC6A4 1319/4885SLC6A3 611/4885 |
| US-20130317055-A1 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE | CHRNA7, CHRNA2, CHRNA5 | SLC6A2 60/4885SLC6A4 437/4885SLC6A3 157/4885 |
| US-20150313891-A1 | NEURONAL NICOTINIC AGONISTS AND METHODS OF USE | CHRNA7, CHRNA2, CHRNA5 | SLC6A2 58/4885SLC6A4 421/4885SLC6A3 148/4885 |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | HTT, ACHE, CHRNA10 | SLC6A2 16/4885SLC6A4 25/4885SLC6A3 7/4885 |
| US-20130317054-A1 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE | CHRNA7, CHRNA2, CHRNA5 | SLC6A2 61/4885SLC6A4 442/4885SLC6A3 161/4885 |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | SLC6A2 400/4885SLC6A4 541/4885SLC6A3 374/4885 |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | SLC6A2 107/4885SLC6A4 290/4885SLC6A3 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.